CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
Pepinemab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03320330
NCT03320330Phase 2Completed
CompareCT.gov

A Phase 1/2 Study of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors

Children's Oncology Group·interventional·Posted Oct 25, 2017·Updated Jul 15, 2024

In Brief

A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Pepinemab, and 1 other intervention for Recurrent Malignant Solid Neoplasm and 3 related conditions. Completed, enrolled 26 participants across 24 sites.

Detailed Summary

This phase I/II trial studies the side effects and best dose of pepinemab and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment. Immunotherapy with monoclonal antibodies, such as pepinemab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedOct 25, 2017
Enrollment StartJan 31, 2018
Primary CompletionDec 31, 2020
Study CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 8.7 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Pepinemabbiological

Given IV

Pharmacological Studyother

Correlative studies